/
BCAX
$29.34+$2.47 (+9.19%)live
Held · Bookmarked
0 · 0
portfolios · users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
Market cap
$1.8B
66M shares
52-week range
$8.58 – $29.38
100% from low
Sector
PHARMACEUTICAL PREPARATIONS
Exchange
NASDAQ
CS
Borrow rate
0.41%
Easy to borrow
Price (6 mo)
Loading chart…
Change+$5.93
Valuation
Financials
Loading chart…
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| Cost of revenue | $0 | $0 | $0 | $0 |
| Gross profit | $0 | $0 | $0 | $0 |
| Gross margin | — | — | — | — |
| R&D | $31.3M | $30.6M | $63.6M | $125.1M |
| Operating income | −$37.7M | −$39.9M | −$82.4M | −$155.6M |
| EBITDA | −$37.7M | −$52.0M | −$67.8M | −$137.6M |
| Net income | −$37.8M | −$52.0M | −$68.0M | −$137.9M |
| Net margin | — | — | — | — |
| EPS (diluted) | -0.73 | -1.00 | -1.25 | -2.52 |
Annual figures · source: Financial Modeling Prep
Analyst estimates (consensus)
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $0 | $-3.49 | $-4.09–$-2.52 | 11 |
| 2027 | $0 | $-3.70 | $-4.63–$-2.64 | 10 |
| 2028 | $42M | $-3.53 | $-4.39–$-2.42 | 10 |
| 2029 | $197M | $-2.49 | $-2.49–$-2.49 | 4 |
Forward consensus · source: Financial Modeling Prep
DCF fair valuemodel estimate
Intrinsic value
$1.64
Price
$29.34
Implied downside
-94%
Peer comparison
Bicara Therapeutics Inc. Common Stock
Bicara Therapeutics Inc is a clinical-stage biopharmaceutical company bringing transformative bifunctional therapies to patients with solid tumors. Its program ficerafusp alfa is a bifunctional antibody that combines two clinically validated targets, an epidermal growth factor receptor, or EGFR, directed monoclonal antibody with a domain that binds to human transforming growth factor beta, or TGF-b. The company's goal is to build a fully integrated, commercial-stage biopharmaceutical company that develops important therapies for people living with cancer, starting with ficerafusp alfa.
www.bicara.com- Employees
- 103
- IPO / List date
- Sep 13, 2024
- HQ
- BOSTON, MA
Held by traders on TradeandTell
No one on the platform currently holds BCAX.
Super investors & insiders
Institutions holding (13F)
No tracked institution reports a position in BCAX as of their last filing.
Insider activity (SEC Form 4)
Recent trades on TradeandTell
No one on the platform has traded BCAX yet.
